Gennova Biopharmaceuticals' mRNA Covid-19 booster vaccine, 'Gemcovac Om', has received emergency use authorisation from the office of the Drugs Controller General of India for the Omicron variant. The vaccine is the first booster Covid-19 vaccine developed in India against the highly transmissible Omicron variant and has demonstrated robust immune responses in phase 3 clinical trials. It is stable at two to eight degrees Centigrade and has been developed using Gennova's indigenous platform technology, supported under 'Mission Covid Suraksha'.